+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Organ Distribution of Radioactivity and Disappearance of Radioactivity from Plasma After Administration of [ 3H] Luteinizing Hormone-Releasing Hormone to Mice and Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Whole-body autoradiography of amouse 5 min after an intrajugular injection of 43 nmoles of l-(4-[<sup>3</sup>H]pyro-Glu)-LH-RH (18.3 Ci/mmole) shows a large accumulation of radio-activity in the pituitary, subcutaneous tissue, intestinal wall, kidney, and bladder. Some radioactivity is also found in the liver, lungs, and heart, but no labeling is seen in the central nervous system. Direct measurements of radioactivity in different organs of the rat 5 min after injection of [<sup>3</sup>H] LH-RH also show that the highest accumulation of radioactivity is in the anterior pituitary gland, kidney, epididymal fat, and skin. Low labeling is measured in the posterior (including intermediate) lobe of the pituitary, pineal, liver, submaxillary gland, testis, adrenal, thyroid, and striated muscle. The pattern of plasma radioactivity after a single intravenous injection of [<sup>3</sup>H] LH-RH can be represented by the sum of four exponents, suggesting a four-compartment model of the disappearance of radioactivity from plasma. The metabolic clearance rate is 1.2 ml/min. The half-life of the first exponent (up to 10 min after injection) is about 7.5 min. 30 sec after injection of [<sup>3</sup>H] LH-RH, the radioactivity is distributed in a total volume of 26.5 ml (approximately 11% of body weight).

          Related collections

          Author and article information

          S. Karger AG
          20 March 2008
          : 16
          : 2
          : 65-73
          MRC Group in Molecular Endocrinology, Centre Hospitalier de l’Université Laval, Quebec, and Endocrine and Polypeptide Laboratories, V.A. Hospital and Tulane University School of Medicine, New Orleans, La.
          122553 Neuroendocrinology 1974;16:65–73
          © 1974 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9


          Comment on this article